HER3‑Targeted Antibody‑Drug Conjugate Research
The division focuses on evaluating a novel HER3‑DXd in patients with advanced cancers that have spread to the central nervous system.
- Intracranial objective response assessment
- Overall survival analysis in leptomeningeal disease
- HER3 expression as a therapeutic target
The studies are conducted at Medical University of Vienna with strong collaboration between academic investigators and commercial partners.
Central Nervous System Metastasis Trials
Clinical investigations address brain metastases arising from Metastatic Breast Cancer and Non‑Small Cell Lung Cancer, aiming to improve treatment outcomes inside the skull.
- Use of Response Assessment in Neuro‑Oncology Brain Metastases (RANO‑BM) criteria
- Evaluation of intracranial objective response rate
- Multi‑cohort design to compare different tumor origins
Over 184 investigators contribute to these trials, reflecting the site’s extensive expertise in neuro‑oncology.
Leptomeningeal Carcinomatosis Studies
A dedicated cohort investigates patients with solid tumors and untreated leptomeningeal disease, testing whether the HER3‑conjugate can extend survival.
- Assessment of three‑month overall survival
- Safety monitoring in the spinal and cranial CSF compartments
- Biomarker analysis of HER3 expression in leptomeningeal cells
The program highlights the department’s commitment to tackling rare and aggressive CNS complications of cancer.
